Nanospatially confined ROS eliminator produced in situ by engineered Escherichia coli Nissle 1917 for oral treatment of inflammatory bowel disease - PubMed
6 hours ago
- #oral-therapy
- #inflammatory-bowel-disease
- #engineered-bacteria
- Engineered Escherichia coli Nissle 1917 used as a probiotic factory for in situ oral treatment of inflammatory bowel disease.
- Nanobiotic reactors produced via bacterial outer membrane vesicles (OMVs) enhanced with SpyCatcher/SpyTag system for targeted protein encapsulation.
- Approach increased OMV generation through protein turnover and oxidative stress, maintaining efficacy in hypoxic colon environments.
- In DSS-induced colitis mice, treatment reduced inflammation, repaired intestinal barrier, and regulated gut microbiota.
- System allows customization for different diseases by swapping therapeutic proteins and adding SpyTag.